Presentation, Licensing Agreement, Trial Milestone, Positive Opinion, and Trade Name Acceptance - Research Report on Pfizer, Allergan, Novartis, AstraZeneca, and Rockwell Medical

NEW YORK, September 30, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Allergan Inc. (NYSE: AGN), Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN), and Rockwell Medical, Inc. (NASDAQ: RMTI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 24, 2013, Pfizer Inc. (Pfizer) announced that 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2013 Annual Meeting, to be held from October 25 to October 30, 2013 in San Diego, CA. According to Pfizer, XELJANZ (tofacitinib citrate) is the first in a new class for the treatment of rheumatoid arthritis (RA), oral Janus kinase (JAK) inhibitors, which is approved in the US for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate, at a dose of 5 mg tablet twice daily. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/d702_PFE]

--

Allergan Inc. Research Report

On September 25, 2013, Allergan Inc. (Allergan) announced that it has entered into a licensing agreement with Medytox, Inc. (Medytox). Allergan reported that pursuant to the agreement it will pay Medytox an upfront payment of $65 million for the exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize certain neurotoxin product candidates which are currently in development, including a potential liquid-injectable product. The Company also reported that it has agreed to make additional contingent payments, including up to an aggregate of $116.5 million upon achieving certain development milestones, up to an aggregate of $180.5 million upon achieving certain commercialization milestones, and royalties on product sales. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/182a_AGN]

--

Novartis AG Research Report

On September 19, 2013, in line with the commemoration of World CML Day, Novartis AG (Novartis) announced the newest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy - a concept called treatment-free remission. Novartis informed that more than 100 study sites are now enrolling patients to the trial program. Hervé Hoppenot, President, Novartis Oncology, stated, "Given that nilotinib has been shown in large clinical trials to drive deeper levels of responses in more than twice as many patients as imatinib, we are now looking to the next phase and exploring if nilotinib can treat the disease to a point where drug therapy is no longer needed, representing the next step in what may be possible for patients living with Ph+ CML." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6d_NVS]

--

AstraZeneca PLC Research Report

On September 20, 2013, AstraZeneca PLC (AstraZeneca) announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on Fluenz Tetra. AstraZeneca reported that Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine, for the prevention of seasonal influenza in eligible children and adolescents 24 months to 17 years of age. Filip Dubovsky, Vice President of Clinical Biologics Infectious Disease and Vaccines, at MedImmune, AstraZeneca's Global Biologics Research and Development arm, commented, "We are delighted that Fluenz Tetra has received a positive opinion from the CHMP. The inclusion of two influenza B strains in the vaccine will provide broad protection and should help to reduce the overall incidence of influenza." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/09cc_AZN]

--

Rockwell Medical, Inc. Research Report

On September 17, 2013, Rockwell Medical, Inc. (Rockwell Medical) announced that the US Food and Drug Administration (FDA) has accepted the proposed proprietary trade name Triferic^[TM] for the Company's investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP). The Company reported that Triferic^[TM] is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell Medical reported that a request for proprietary name review for Triferic will be filed with the New Drug Application (NDA) submission. Rob Chioini, Founder, Chairman, and CEO of Rockwell Medical, stated, "Securing Triferic^[TM] as our proposed trade name is yet another important milestone we have accomplished as we continue our advancement towards obtaining FDA marketing approval." Chioini continued, "Our clinical team continues to work diligently on reviewing the successful Phase 3 CRUISE-1 and CRUISE-2 study data which, together with our successful PRIME study results demonstrating Triferic^[TM] can significantly reduce ESA use, supports our belief that Triferic^[TM] will establish a new paradigm in iron therapy treatment for hemodialysis patients. We believe that upon FDA approval, Triferic^[TM] will become the new standard of care in iron therapy." The Full Research Report on Rockwell Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/3079_RMTI]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner